Hypertriglyceridemia Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer Biologics, Ionis Pharmaceuticals, Inc., GeneCradle, MediciNova, Regeneron

Hypertriglyceridemia Pipeline constitutes 18+ key companies continuously working towards developing 20+ Hypertriglyceridemia treatment therapies, analyzes DelveInsight.

Hypertriglyceridemia Overview:

Hypertriglyceridemia is a condition marked by high triglyceride levels in the blood, which can increase the risk of cardiovascular disease (CVD) and acute pancreatitis. It is commonly linked to factors such as uncontrolled diabetes, obesity, physical inactivity, and genetics. Typically, the condition remains without symptoms until triglyceride levels surpass 1,000-2,000 mg/dL, at which point complications like pancreatitis and metabolic imbalances may occur. Management focuses on lifestyle changes-including diet modification, weight reduction, and regular exercise-supplemented by medications such as statins or fibrates when needed. Effective control also requires monitoring and treating underlying health issues to reduce associated risks.

Request for a detailed insights report on Hypertriglyceridemia pipeline insights https://www.delveinsight.com/report-store/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Hypertriglyceridemia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hypertriglyceridemia Therapeutics Market.

Key Takeaways from the Hypertriglyceridemia Pipeline Report

DelveInsight's Hypertriglyceridemia pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Hypertriglyceridemia treatment.
In December 2024, the FDA approved Tryngolza (olezarsen) as the first-ever treatment for familial chylomicronemia syndrome (FCS)-a profoundly rare and severe form of hypertriglyceridemia.
Arrowhead Pharmaceuticals' plozasiran has had its New Drug Application (NDA) accepted by the FDA in January 2025, with a PDUFA deadline set for November 18, 2025.
Key Hypertriglyceridemia companies such as NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer Biologics, Ionis Pharmaceuticals, Inc., GeneCradle, MediciNova, Regeneron Pharmaceuticals, and others are evaluating new drugs for Hypertriglyceridemia to improve the treatment landscape.
Promising Hypertriglyceridemia pipeline therapies in various stages of development include SEFA-1024, DR10624, GC304, and others.

Hypertriglyceridemia Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Hypertriglyceridemia Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertriglyceridemia treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hypertriglyceridemia market.

Download our free sample page report on Hypertriglyceridemia pipeline insights https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hypertriglyceridemia Emerging Drugs

SEFA-1024 - NorthSea Therapeutics

SEFA-1024 is an oral, gut/liver-targeted semi-synthetic eicosapentaenoic acid derivative under development for severe hypertriglyceridemia (sHTG), a condition that markedly raises the risk of acute pancreatitis and may increase cardiovascular event risk. Current therapies often show limited efficacy in lowering triglycerides (TG), non-HDL cholesterol, and improving glycemic control, leaving a notable unmet medical need. Backed by strong preclinical data from a human-translatable HTG model, SEFA-1024 shows potential to address these gaps. The drug is currently in Phase II clinical trials for hypertriglyceridemia.
DR10624 - Doer Biologics
DR10624 is a first-in-class, long-acting tri-agonist that targets FGF21R, GLP-1R, and the glucagon receptor (GCGR). Developed using Doer Bio's proprietary MultipleBody platform, it is designed for balanced activity in metabolic disease management. Non-clinical studies have shown DR10624 to significantly reduce body weight, lower triglycerides, normalize blood lipid levels, and improve liver function. It is currently in Phase II clinical development for severe hypertriglyceridemia.

Hypertriglyceridemia Companies

Around 18 or more key companies are actively developing therapies for hypertriglyceridemia, with NorthSea Therapeutics among those having drug candidates in the most advanced stage of development-Phase II.

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Hypertriglyceridemia Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Hypertriglyceridemia Therapies and Key Companies: Hypertriglyceridemia Clinical Trials and advancements https://www.delveinsight.com/report-store/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hypertriglyceridemia Pipeline Therapeutic Assessment
• Hypertriglyceridemia Assessment by Product Type
• Hypertriglyceridemia By Stage
• Hypertriglyceridemia Assessment by Route of Administration
• Hypertriglyceridemia Assessment by Molecule Type

Download Hypertriglyceridemia Sample report to know in detail about the Hypertriglyceridemia treatment market @ Hypertriglyceridemia Therapeutic Assessment https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.